Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: Comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2214-2217

  Miglino, Maurizio ^a   Colombo, Nicoletta ^a   Grasso, Raffaella ^a   Marani, Carlo ^a   Clavio, Marino ^a   Pica, Gian Matteo ^a   Ballerini, Filippo ^a   Ghiggi, Chiara ^a   Minetto, Paola ^a   Guolo, Fabio ^a   Carella, Angelo Michele ^a   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

AML; MRD; NPM; WT1

Indexed keywords

NUCLEOPHOSMIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOFLUOROMETRY; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; AGED; DISEASE-FREE SURVIVAL; FLOW CYTOMETRY; GENES, WILMS TUMOR; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS;

EID: 84867152043     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.681658     Document Type: Article

References (24)

1. van Dongen JJ, Seriu T, Panzer-Gr ü mayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-1738. (Pubitemid 28534955)
2. Grimwade D, Howe K, Langabeer S, et al. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 1996;10:61-66. (Pubitemid 26052981)
3. Bahia DM, Yamamoto M, Chauf aille Mde L, et al. Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical signifcance. Haematologica 2001;86:801-806. (Pubitemid 32847440)
4. Kern W, Bacher U, Haferlach C, et al. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010;23:379-390.
5. Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104:3078-3085. (Pubitemid 39517010)
6. San Miguel JF, Vidriales MB, L ó pez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identif es dif erent patient risk groups and may contribute to postinduction treatment stratif cation. Blood 2001;98:1746-1751.
7. Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006;20:1783-1789. (Pubitemid 44590961)
8. Marcucci G, Caligiuri MA, D ö hner H, et al. Quantif cation of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with inv(16) acute myeloid leukemia. Leukemia 2001;15:1072-1080. (Pubitemid 32717277)
9. Schnittger S, Weisser M, Schoch C, et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11 + acute myeloid leukemia based on quantif cation of fusion transcripts. Blood 2003;102:2746-2755. (Pubitemid 37248843)
10. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantif cation in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004;112:79-84. (Pubitemid 38716252)
11. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-266. (Pubitemid 40110814)
12. Chou WC, Tang JL, Wu SJ, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007;21:998-1004.
13. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specif c RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220-2231.
14. Kr ö nke J, Schlenk RF, Jensen K-O, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 2011;29:2709-2716.
15. Papadaki C, Dufour A, Seibl M, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009;144:517-523.
16. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854-2861. (Pubitemid 41510764)
17. Vardiman JW, T iele J, Arber DA, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
18. Inoue K, Ogawa H, Yamagami T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88:2267-2278. (Pubitemid 26307931)
19. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-3080. (Pubitemid 29200800)
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117:1109-1120.
22. Miglino M, Colombo N, Pica G, et al. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leuk Lymphoma 2011;52:1961-1969.
23. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2009;113:1875-1891.
24. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010;28:3724-3729.